1 active not recruiting, 1 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Active not recruiting 1, Completed 1 |
Follow siponimod: new trials by email Literature Review of siponimod trials Research Report on siponimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) BAF312, Baseline disease modifying therapies (DMTs), BNT162 - Secondary Progressive Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 41 | 2021-04-19 | 2024-06-20 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
COVID-19 (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Novartis Pharmaceuticals (1) · The Cleveland Clinic (1)
Germany (1) · United Kingdom (1) · United States (1)
Daniel Ontaneda, MD, MSc (1) · Nikos Evangelou, MD, DPhil (1)